796 related articles for article (PubMed ID: 34758252)
1. Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
Pfeffer MA; Claggett B; Lewis EF; Granger CB; Køber L; Maggioni AP; Mann DL; McMurray JJV; Rouleau JL; Solomon SD; Steg PG; Berwanger O; Cikes M; De Pasquale CG; East C; Fernandez A; Jering K; Landmesser U; Mehran R; Merkely B; Vaghaiwalla Mody F; Petrie MC; Petrov I; Schou M; Senni M; Sim D; van der Meer P; Lefkowitz M; Zhou Y; Gong J; Braunwald E;
N Engl J Med; 2021 Nov; 385(20):1845-1855. PubMed ID: 34758252
[TBL] [Abstract][Full Text] [Related]
2. The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial.
Mehran R; Steg PG; Pfeffer MA; Jering K; Claggett B; Lewis EF; Granger C; Køber L; Maggioni A; Mann DL; McMurray JJV; Rouleau JL; Solomon SD; Ducrocq G; Berwanger O; De Pasquale CG; Landmesser U; Petrie M; Leng DSK; van der Meer P; Lefkowitz M; Zhou Y; Braunwald E
Circulation; 2022 Dec; 146(23):1749-1757. PubMed ID: 36321459
[TBL] [Abstract][Full Text] [Related]
3. Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial.
Berwanger O; Pfeffer M; Claggett B; Jering KS; Maggioni AP; Steg PG; Mehran R; Lewis EF; Zhou Y; van der Meer P; De Pasquale C; Merkely B; Filippatos G; McMurray JJV; Granger CB; Solomon SD; Braunwald E
Eur J Heart Fail; 2022 Oct; 24(10):1918-1927. PubMed ID: 36054480
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin Receptor-Neprilysin Inhibitor in Acute Myocardial Infarction.
Pathak P
J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443387
[TBL] [Abstract][Full Text] [Related]
5. Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy.
Shah AM; Claggett B; Prasad N; Li G; Volquez M; Jering K; Cikes M; Kovacs A; Mullens W; Nicolau JC; Køber L; van der Meer P; Jhund PS; Ibram G; Lefkowitz M; Zhou Y; Solomon SD; Pfeffer MA
Circulation; 2022 Oct; 146(14):1067-1081. PubMed ID: 36082663
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Sacubitril-Valsartan in Patients With Reduced Left Ventricular Ejection Fraction.
Briasoulis A; Kuno T; Ueyama H
Am J Cardiol; 2021 Aug; 153():150-152. PubMed ID: 34210504
[No Abstract] [Full Text] [Related]
7. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
[TBL] [Abstract][Full Text] [Related]
8. Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trial.
Schou M; Claggett B; Miao ZM; Fernandez A; Filippatos G; Granger C; Jering K; Maggioni AP; McCausland F; Villota JN; Rouleau JL; Mody FV; van der Meer P; Vinereanu D; McGrath M; Zhou Y; Mann DL; Solomon SD; Steg PG; Braunwald E; McMurray JJV; Pfeffer MA; Køber L
Eur J Heart Fail; 2024 Jan; 26(1):130-139. PubMed ID: 37933184
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI.
Mann DL; Nicolas J; Claggett B; Miao ZM; Granger CB; Kerkar P; Køber L; Lewis EF; McMurray JJV; Maggioni AP; Núñez J; Ntsekhe M; Rouleau JL; Sim D; Solomon SD; Steg PG; van der Meer P; Braunwald E; Pfeffer MA; Mehran R
J Am Coll Cardiol; 2024 Mar; 83(9):904-914. PubMed ID: 38418004
[TBL] [Abstract][Full Text] [Related]
10. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Efficacy and Safety of Sacubitril/Valsartan versus Ramipril in Patients With ST-Segment Elevation Myocardial Infarction.
Rezq A; Saad M; El Nozahi M
Am J Cardiol; 2021 Mar; 143():7-13. PubMed ID: 33417876
[TBL] [Abstract][Full Text] [Related]
13. Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics.
Jering KS; Claggett B; Pfeffer MA; Granger C; Køber L; Lewis EF; Maggioni AP; Mann D; McMurray JJV; Rouleau JL; Solomon SD; Steg PG; van der Meer P; Wernsing M; Carter K; Guo W; Zhou Y; Lefkowitz M; Gong J; Wang Y; Merkely B; Macin SM; Shah U; Nicolau JC; Braunwald E
Eur J Heart Fail; 2021 Jun; 23(6):1040-1048. PubMed ID: 33847047
[TBL] [Abstract][Full Text] [Related]
14. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
[TBL] [Abstract][Full Text] [Related]
15. Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.
Greene SJ; Choi S; Lippmann SJ; Mentz RJ; Greiner MA; Hardy NC; Hammill BG; Luo N; Samsky MD; Heidenreich PA; Laskey WK; Yancy CW; Peterson PN; Curtis LH; Hernandez AF; Fonarow GC; O'Brien EC
J Am Heart Assoc; 2021 Aug; 10(16):e021459. PubMed ID: 34350772
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study.
Jain AR; Aggarwal RK; Rao NS; Billa G; Kumar S
Indian Heart J; 2020; 72(6):535-540. PubMed ID: 33357641
[TBL] [Abstract][Full Text] [Related]
17. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
Rohde LE; Claggett BL; Wolsk E; Packer M; Zile M; Swedberg K; Rouleau J; Pfeffer MA; Desai AS; Lund LH; Kober L; Anand I; Merkely B; Senni M; Shi V; Rizkala A; Lefkowitz M; McMurray JJV; Solomon SD
Circ Heart Fail; 2021 Mar; 14(3):e008052. PubMed ID: 33706551
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial.
Berg DD; Samsky MD; Velazquez EJ; Duffy CI; Gurmu Y; Braunwald E; Morrow DA; DeVore AD
Circ Heart Fail; 2021 Feb; 14(2):e007034. PubMed ID: 33530704
[TBL] [Abstract][Full Text] [Related]
19. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.
Okumura N; Jhund PS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJ;
Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27618854
[TBL] [Abstract][Full Text] [Related]
20. Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis.
Aimo A; Pateras K; Stamatelopoulos K; Bayes-Genis A; Lombardi CM; Passino C; Emdin M; Georgiopoulos G
Cardiovasc Drugs Ther; 2021 Oct; 35(5):1067-1076. PubMed ID: 33074526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
